Lucid Diagnostics opened higher at $0.40, compared with its previous close of $0.38. In the last trading session, the stock traded between $0.38 and $0.43. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Lucid Diagnostics is now worth
$ 4.34
Resulting in a loss of
$ 95.66 (95.66%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.04 (+9.86%)
Day High
$0.43
Day Low
$0.38
Day Open
$0.40
Prev Close
$0.38
Volume
22,42,030
1W Return
-6.47%
1M Return
-30.17%
3M Return
-56.35%
6M Return
-58.92%
1Y Return
-59.71%
Fundamentals
Market Cap ($ Mn)
85
PE Ratio
-
PB Ratio
17.42
PEG Ratio
-
ROE
-
ROCE
-566.56%
EPS (TTM)
$-0.08
Investment Returns
1 Week
-6.47%
1 Month
-30.17%
3 Months
-56.35%
6 Months
-58.92%
9 Months
-65.08%
Financials
Quarterly
All values in $ Mn
0.8
Mar 25
1.2
Jun 25
1.2
Sep 25
1.5
Dec 25
1.3
Mar 26
1.5
Jun 26
Updates
3Nov
Lucid Diagnostics publishes 11,991-patient real-world EsoGuard study
Study covers 11,991 patients with 95% cell collection success rate. Average collection time under 2 minutes with zero device-related adverse events. 82% of patients reported very low discomfort; 96% would recommend the test. Findings support large-scale implementation as Medicare reimbursement expands.
9 days ago
22Sep
Lucid Diagnostics advances EsoGuard and EsoCheck payment pathways
CMS panel recommends maintaining original gapfill payment basis for EsoGuard under CLFS. AMA approves new Category III CPT code for non-endoscopic esophageal cell collection. CDC/NCHS committee favors proposed ICD-10-CM code R85.83 for positive EsoGuard results. Texas laboratory begins Medicare claim submissions this month; California lab awaits LCD update.
1mo ago
13Aug
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage
Lucid Diagnostics reported Q2 2026 revenue of $1.5 million, up 17% sequentially, driven by 2,770 EsoGuard tests. The company secured its first LBM coverage policy from Concert and maintains $33.4 million in cash with a $11.3 million quarterly burn rate. Revenue recognition remains constrained by collection probabilities, though contracted revenue mix is improving.
3mo ago
8Jun
Lucid Diagnostics eyes strong 2026 growth despite Q1 miss
Lucid Diagnostics missed Q1 revenue expectations but is poised for significant growth in 2026 and 2027, supported by a $40 million potential revenue backlog and anticipated Medicare coverage. Analyst Edward Woo maintained a Buy rating and raised the price target to $9.25.
